DFT calculations show that doping Cu-based paddlewheel MOFs leads to more selective CO2 reduction products.
Diruthenium(II,III) paddlewheel carboxylates combine the pharmacological properties of the dimetallic center with those ascribed to the μ-bridged carboxylates, thus leading to novel, dual-acting anticancer metallodrugs.
Dirhodium tetracarboxylate complexes catalyze a number of useful carbenoid transformations including cyclopropanation and C–H functionalization.
A study of the protein binding properties of diruthenium compounds depending on the charge of the complexes generated in solution.
This work presents an axially chiral platform based on ruthenium units, evaluates the crystal structures, configurational stability and electronic structure tunability, and proposes a general nomenclature system for binuclear paddlewheel complexes.